Journal
PHARMACOGENETICS AND GENOMICS
Volume 23, Issue 4, Pages 242-248Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e32835f1cc0
Keywords
allele; nomenclature; pharmacogenetics; thiopurine methyltransferase
Funding
- Swedish Children's Cancer Foundation
- Swedish Cancer Society
- NHMRC
- Gutsy Group
- NIH [R37 CA 36401, U01 GM 92666, U01 HL 105918, P30 CA 21765, UL1 RR025747, P01CA142538, GM 92666, HL 105918, U19 GM61388, RO1 GM28157, RO1 CA132780, R24 GM61374]
- ALSAC
- Jim and Mary Carney Charitable Trust, Whangarei, New Zealand
- Leukaemia and Lymphoma Research, London, UK
- Guy's and St Thomas' Charity
- Robert Bosch Foundation, Stuttgart
- Deutsche Forschungsgemeinschaft, Germany [SFB685]
- Children's Cancer Foundation, Singapore
- Newcastle Healthcare Charity
- Newcastle upon Tyne Hospitals NHS Charity
Ask authors/readers for more resources
The drug-metabolizing enzyme thiopurine methyltransferase (TPMT) has become one of the best examples of pharmacogenomics to be translated into routine clinical practice. TPMT metabolizes the thiopurines 6-mercaptopurine, 6-thioguanine, and azathioprine, drugs that are widely used for treatment of acute leukemias, inflammatory bowel diseases, and other disorders of immune regulation. Since the discovery of genetic polymorphisms in the TPMT gene, many sequence variants that cause a decreased enzyme activity have been identified and characterized. Increasingly, to optimize dose, pretreatment determination of TPMT status before commencing thiopurine therapy is now routine in many countries. Novel TPMT sequence variants are currently numbered sequentially using PubMed as a source of information; however, this has caused some problems as exemplified by two instances in which authors' articles appeared on PubMed at the same time, resulting in the same allele numbers given to different polymorphisms. Hence, there is an urgent need to establish an order and consensus to the numbering of known and novel TPMT sequence variants. To address this problem, a TPMT nomenclature committee was formed in 2010, to define the nomenclature and numbering of novel variants for the TPMT gene. A website (http://www.imh.liu.se/tpmtalleles) serves as a platform for this work. Researchers are encouraged to submit novel TPMT alleles to the committee for designation and reservation of unique allele numbers. The committee has decided to renumber two alleles: nucleotide position 106 (G>A) from TPMT*24 to TPMT*30 and position 611 (T>C, rs79901429) from TPMT*28 to TPMT*31. Nomenclature for all other known alleles remains unchanged. Pharmacogenetics and Genomics 23: 242-248 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. Pharmacogenetics and Genomics 2013, 23:242-248
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available